DSpace Repository

Reply to "Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future"

Show simple item record

dc.contributor.author Requena-Mendez, Ana
dc.contributor.author Davies, Geraint
dc.contributor.author Moore, David A. J.
dc.date.accessioned 2019-02-06T14:59:05Z
dc.date.available 2019-02-06T14:59:05Z
dc.date.issued 2015
dc.identifier.uri https://hdl.handle.net/20.500.12866/5513
dc.description.abstract We thank Sturkenboom et al. for their interest in our study and their comments. The pragmatic study design based on two sampling points, 2 and 6 h after drug intake, reflected the real-world approach taken in this study, sampling patients attending a government clinic rather than in the controlled setting of a pharmacokinetic study suite. This sampling strategy has frequently been used in the past, and there are data to suggest that the peak serum concentration (Cmax) occurs between 1 and 2 h postdose when isoniazid is given on an empty stomach. If only isoniazid is being measured, a two-sample strategy with estimation of 1- and 4-h concentrations may effectively capture both the Cmax and the majority of delayed absorption. However, isoniazid is usually administered with other drugs which are somewhat more slowly absorbed (e.g., rifampin). In such cases, a 2- and 6-h-postdose sampling strategy facilitating study of both agents seems reasonable. In our study, the objective was to determine the pharmacokinetics of isoniazid and also rifampin, and thus the C2-C6 sampling strategy was chosen. Although a more intensive pharmacokinetic sampling would better capture the true Cmax values, as suggested by the authors, the logistical demands of this approach would have compromised study recruitment in most of our community clinic field sites, rendering the study unfeasible... en_US
dc.language.iso eng
dc.publisher American Society for Microbiology
dc.relation.ispartof urn:issn:1098-6596
dc.rights info:eu-repo/semantics/restrictedAccess
dc.rights.uri https://creativecommons.org/licenses/by-nc-nd/4.0/deed.es
dc.subject Female en_US
dc.subject Humans en_US
dc.subject Male en_US
dc.subject Food-Drug Interactions en_US
dc.subject Antitubercular Agents/pharmacokinetics en_US
dc.subject Dietary Fats/pharmacokinetics en_US
dc.subject Isoniazid/pharmacokinetics en_US
dc.subject Rifampin/pharmacokinetics en_US
dc.subject Tuberculosis, Pulmonary/drug therapy en_US
dc.title Reply to "Adequate design of pharmacokinetic-pharmacodynamic studies will help optimize tuberculosis treatment for the future" en_US
dc.type info:eu-repo/semantics/article
dc.identifier.doi https://doi.org/10.1128/AAC.05182-14
dc.subject.ocde https://purl.org/pe-repo/ocde/ford#3.02.00 es_PE


Files in this item

Files Size Format View

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record

info:eu-repo/semantics/restrictedAccess Except where otherwise noted, this item's license is described as info:eu-repo/semantics/restrictedAccess

Search DSpace


Browse

My Account

Statistics